Blonski J - Search Results

1

Insignificant prostate cancer in radical prostatectomy specimen: time trends and preoperative prediction.

Augustin H, Hammerer PG, Graefen M, Erbersdobler A, Blonski J, Palisaar J, Daghofer F, Huland H. Augustin H, et al. Among authors: blonski j. Eur Urol. 2003 May;43(5):455-60. doi: 10.1016/s0302-2838(03)00139-8. Eur Urol. 2003. PMID: 12705986

2

Can predictive models for prostate cancer patients derived in the United States of America be utilized in European patients? A validation study of the Partin tables.

Graefen M, Augustin H, Karakiewicz PI, Hammerer PG, Haese A, Palisaar J, Blonski J, Fernandez S, Erbersdobler A, Huland H. Graefen M, et al. Among authors: blonski j. Eur Urol. 2003 Jan;43(1):6-10; discussion 11. doi: 10.1016/s0302-2838(02)00497-9. Eur Urol. 2003. PMID: 12507538

3

Zonal location of prostate cancer: significance for disease-free survival after radical prostatectomy?

Augustin H, Hammerer PG, Blonski J, Graefen M, Palisaar J, Daghofer F, Huland H, Erbersdobler A. Augustin H, et al. Among authors: blonski j. Urology. 2003 Jul;62(1):79-85. doi: 10.1016/s0090-4295(03)00248-6. Urology. 2003. PMID: 12837427

4

Prognostic significance of visible lesions on transrectal ultrasound in impalpable prostate cancers: implications for staging.

Augustin H, Graefen M, Palisaar J, Blonski J, Erbersdobler A, Daghofer F, Huland H, Hammerer PG. Augustin H, et al. Among authors: blonski j. J Clin Oncol. 2003 Aug 1;21(15):2860-8. doi: 10.1200/JCO.2003.11.130. J Clin Oncol. 2003. PMID: 12885802

5

[Influence of transrectal endosonography on the clinical staging of impalpable prostate cancer. A controversy over the TNM system].

Hammerer PG, Augustin H, Blonski J, Graefen M, Haese A, Erbersdobler A, Daghofer F, Huland H. Hammerer PG, et al. Among authors: blonski j. Urologe A. 2004 Mar;43(3):307-12. doi: 10.1007/s00120-004-0531-8. Urologe A. 2004. PMID: 15045191 Clinical Trial. German. No abstract available.

6

Increased abundance of Firmicutes and depletion of Bacteroidota predicts poor outcome in chronic lymphocytic leukemia.

Paziewska M, Szelest M, Kiełbus M, Masternak M, Zaleska J, Wawrzyniak E, Kotkowska A, Siemieniuk-Ryś M, Morawska M, Kalicińska E, Jabłonowska P, Wróbel T, Wolska-Washer A, Błoński JZ, Robak T, Bullinger L, Giannopoulos K. Paziewska M, et al. Among authors: blonski jz. Oncol Lett. 2024 Sep 17;28(5):552. doi: 10.3892/ol.2024.14685. eCollection 2024 Nov. Oncol Lett. 2024. PMID: 39328278 Free PMC article.

7

A 5-year follow-up to evaluate the efficacy and safety of ofatumumab added to fludarabine and cyclophosphamide in patients with relapsed chronic lymphocytic leukemia: final analysis of the COMPLEMENT 2 trial.

Grosicki S, Lech-Maranda E, Govind Babu K, Rybka J, Litvinskaya E, Loscertales J, Kriachok I, Kłoczko J, Rekhtman G, Homenda W, Blonski J, Stefanelli T, Vincent G, Banerjee H, Robak T. Grosicki S, et al. Among authors: blonski j. Leuk Lymphoma. 2020 Jul;61(7):1748-1751. doi: 10.1080/10428194.2020.1732960. Epub 2020 Feb 28. Leuk Lymphoma. 2020. PMID: 32107948 No abstract available.

8

Dose and drug changes in chronic lymphocytic leukemia cell response in vitro: A comparison of standard therapy regimens with two novel cyclin‑dependent kinase inhibitors.

Kubczak M, Szustka A, Błoński JZ, Gucký T, Misiewicz M, Krystof V, Robak P, Rogalińska M. Kubczak M, et al. Among authors: blonski jz. Mol Med Rep. 2019 May;19(5):3593-3603. doi: 10.3892/mmr.2019.10007. Epub 2019 Mar 5. Mol Med Rep. 2019. PMID: 30864706 Free PMC article.

9

Bendamustine alone or with rituximab modifies expression of apoptosis-regulating genes and proteins of CLL cells, depending on IGVH mutational status.

Ziolkowska E, Wolowiec D, Karpinski P, Blonski JZ, Lech-Maranda E, Borowiec M, Balcerczak E, Sasiadek M, Robak T, Korycka-Wolowiec A. Ziolkowska E, et al. Among authors: blonski jz. Leuk Lymphoma. 2019 Jun;60(6):1409-1419. doi: 10.1080/10428194.2018.1493730. Epub 2018 Sep 6. Leuk Lymphoma. 2019. PMID: 30187811

10

Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial.

Robak T, Błoński J, Skotnicki AB, Piotrowska M, Wróbel T, Rybka J, Kłoczko J, Bołkun Ł, Budziszewska BK, Walczak U, Uss A, Fidecka M, Smolewski P. Robak T, et al. Among authors: blonski j. Eur J Haematol. 2018 May;100(5):465-474. doi: 10.1111/ejh.13042. Epub 2018 Mar 22. Eur J Haematol. 2018. PMID: 29427355 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

98 results

Search Page

Filters